Illumina is engaged in sequencing- and array-based solutions for genetic and genomic analysis. Co.'s products and services enable the adoption of genomic solutions in research and clinical settings. Co.'s principal products, services, and technologies are: sequencing, which includes Deoxyribonucleic acid (DNA) sequencing, a process of determining the order of nucleotide bases (A, C, G, or T) in a DNA sample; arrays, which are used for a range of DNA and RNA analysis applications; consumables, which Co. has developed various library preparation and sequencing kits; and services, which provides whole-genome sequencing, genotyping, noninvasive prenatal testing, and product support services. The ILMN stock yearly return is shown above.
The yearly return on the ILMN stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2023 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the ILMN annual return calculation with any dividends reinvested as applicable (on ex-dates).
|